COVID-19 continues to mutate. Does the vaccine still work?

Without physical contact, the infected person completes the transmission within 14 seconds; In just 10 days, it spread five generations in Guangzhou; Many vaccinated personnel in Nanjing, Yangzhou and other places have also been infected   No one had thought that more than a year after the outbreak of COVID-19, a more infectious Delta mutant has spread again in more than 130 countries and regions around the world.

  “Delta is the most widely disseminated SARS-CoV-2 variant so far,” Dr.

MariaVanKerkhove, COVID-19 technology director of the World Health Organization, issued a warning in July 30, 2021.

“Viruses are evolving and we must reduce harm as far as possible.”   Delta mutant captured the world picture from   ourworldindata   Among those who are hesitant about the novel coronavirus vaccine, the most common concern is that these vaccines “lack long-term safety data”.

  After all, it is only two or three years from the outbreak of the epidemic to vaccine research, testing and marketing.

  Within a few weeks after vaccination, some adverse reactions are extremely rare.

  According to the data of CDC vaccine adverse event reporting system (VAERS) in the United States, several cases of myocarditis were found after vaccination with novel coronavirus vaccine.

  What is the probability of myocarditis?   According to the statistical results of myocarditis after mRNA vaccination released by FDA in June, 16.1 cases of myocarditis (the second injection) occurred per 1 million injections among the population aged 16 to 39, of which the probability of myocarditis after the second injection was higher than that of the first injection, and the probability of Moderna vaccine was higher than that of bnt162b2 vaccine.

  Picture from   medicaldialogues   The CDC Advisory Committee on immunization practice said in a statement that at present, myocarditis usually occurs within 4 days after vaccination, and the vast majority of cases are mild.

  At the same time, after complete vaccination and stable immune response, humoral immunity decreased slowly and gradually stabilized at the effective level, and then the risk of serious complications related to immune response also decreased.

Most adverse reactions of vaccine are transient and will disappear in a few days.

  Even if the probability of myocarditis is extremely rare and the symptoms are not serious, many people are still worried.

However, in fact, if infected with COVID-19 without vaccination, the probability of contracting myocarditis will be higher.

  Why vaccinate?   Now delta mutant has swept the world with high infectivity.

Many vaccinated people are also infected with the virus, which makes more people hesitate – will the virus continue to mutate? Is the vaccine still useful?   Although the virus mutates very fast, it does not mean that the vaccine fails.

  According to the guardian’s interview with Professor FrancoisBalloux, COVID-19’s evolution is quite regular.

These three variants can reduce the efficiency of the existing vaccine to some extent, but it will not cause the vaccine to be totally invalid.

  In the face of delta, vaccination is still the most effective way for ordinary people to prevent the virus.

  On July 22, the New England Journal of Medicine (NEJM) published a research paper on the protective effect of vaccine on Delta mutant strain online.

The results showed that mRNA vaccine bnt162b2 and adenovirus vector vaccine chadox1ncov-19 could effectively prevent symptomatic infection caused by delta mutant strain (also known as b.1.617.2) first found in India.

The protective efficacy of two doses of bnt162b2 vaccine against delta mutant was 88.0%.

Picture from   EffectivenessofCovid-19VaccinesagainsttheB.1.617.2(Delta)Variant   In other words, after vaccination, if you are infected with the virus, the vaccine induced antibody can reduce the risk of disease by 88%.

For the group, the incidence rate of inoculated persons is 88% lower than those without vaccination.

  FDA has officially approved the marketing of mRNA vaccine   On August 23, the US Food and Drug Administration (FDA) fully approved bnt162b2 vaccine.

The formal approval of the vaccine applies to Americans aged 16 and over, while the emergency use authorization is still valid for adolescents aged 12 to 15.

  In fact, bnt162b2 was granted emergency use right by FDA last December.

So far, biontech has provided more than 1.2 billion doses of the novel coronavirus vaccine to more than 120 countries or regions around the world.

  Picture from   theverge   So what is the difference between “emergency use authorization” and “full approval”?   First of all, “emergency use authorization” is to approve the use of medical and epidemic prevention in a certain period of time, a small range and a small group.

  In other words, the situation is urgent.

Although it is understood that everyone is anxious to popularize the vaccine, there are still risks in such medical and epidemic prevention behaviors because the safety has not been tested by sufficient time and evidence, so it can not be popularized on a large scale.

  The “full approval” can be regarded as the full recognition of the effectiveness and safety of the vaccine by FDA.

  Mrnabnt162b2 novel coronavirus vaccine is the first novel coronavirus vaccine approved by FDA so far, and it is also the first novel coronavirus vaccine officially approved in the world with complete phase III data.

  Janet Woodcock, acting director of the FDA, also “endorsed” the mRNA vaccine in the statement – “the public can fully believe that the vaccine meets the FDA’s high standards for the safety, effectiveness and production quality of approved products.” although many people have been vaccinated with different types of novel coronavirus vaccines, for some people, An FDA approved vaccine will give the public more confidence in vaccination.

  Perhaps you don’t know that Fosun Pharmaceutical, a Chinese pharmaceutical company, has also participated in the joint R & D process of this vaccine.

During the global joint research and development of biontechse, Fosun Pharmaceutical cooperated with the Chinese Academy of Medical Sciences to complete animal trials of several mRNA candidate vaccines, and conducted in-depth cooperation with Germany in clinical research, pharmacological data, pharmacovigilance and other aspects.

  I believe that soon, we will also have the opportunity to get mRNA vaccine.

  According to Fosun medicine, the approval of conditional listing of this vaccine in China is under normal progress.

Once approved in China, Fosun Pharmaceutical and biontech will quickly promote the domestic localized production of vaccines and make them become domestic mRNA vaccines.

  How far are we from effective mass immunization?   According to the national health and Health Committee, as of August 29, 2021, 31 provinces (autonomous regions and municipalities directly under the central government) and the Xinjiang production and Construction Corps reported 2 billion 44 million 625 thousand doses of COVID-19 vaccine, and nearly 900 million of them completed the whole process.

  According to China’s census in May 2021, there are about 1.41 billion people in 31 provinces (autonomous regions and municipalities directly under the central government) and Xinjiang production and Construction Corps.

It can be estimated that at present, about 55% of the population in China has completed the whole process of vaccination.

  Earlier, at a public meeting on August 20, academician Zhong Nanshan said: “the effective rate of vaccine in China is about 70%, and more than 80% of the whole population needs to be vaccinated before an effective mass immunization can be established.”   Picture from   thepathmagazine   If calculated according to the population of 1.41 billion, in order to achieve vaccination for more than 80% of the population, about 350 million people in China need to complete two doses of vaccination, that is, about 700 million doses..